Connect with us

Hi, what are you looking for?


Moderna withholds declaring ‘early success’ for its Influenza vaccine

Shares of Moderna Inc (NASDAQ: MRNA) are trading down on Tuesday after the biotechnology company said it did not have enough data to declare “early success” for its Influenza vaccine.

Reason for the delay

“DSMB” – the Data and Safety Monitoring Board has recommended that Moderna continues testing as its recent late-stage trial for mRNA-1010 “did not accrue sufficient cases”.

Also on Tuesday, the Nasdaq-listed firm said it will launch six major vaccines over the next few years. One of them will likely be its first bacterial vaccine against the Lyme disease.

Earlier this year, the biotech company said its respiratory syncytial virus vaccine showed promising results in older adults as Invezz reported HERE. Moderna shares are down nearly 25% versus their year-to-date high at writing.

Moderna COVID-19 vaccine update

Moderna has also recently started a Phase 3 trial for mRNA-1283 – its next-generation, refrigerator-stable COVID-19 vaccine. Its press release reads:

The annual global endemic COVID-19 booster market alone is estimated by Moderna to be approximately $15 billion. The Company estimates respiratory product sales in 2027 to be in the range of $8.0 billion to $15 billion.

The Cambridge-headquartered company is expected to report its Q1 results in the first week of next month. Consensus is for it to lose $1.73 per share this quarter – down sharply from $8.58 of EPS a year ago.

Still, Wall Street has a consensus “overweight” rating on Moderna shares with upside to $225 that suggests about a 50% premium on the current price.

The post Moderna withholds declaring ‘early success’ for its Influenza vaccine appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Latest News

    Rep. Jennifer Wexton (D-Va.) announced on Tuesday that she has been diagnosed with Parkinson’s Disease. “If there’s one thing that Democrats and Republicans can...

    Latest News

    After Dianne Feinstein announced she’d contracted the shingles in early March, her staff said she planned to return to the Senate within a matter...


    A U.S. District Court judge has ruled that Elizabeth Holmes, founder and CEO of the disgraced blood-testing company Theranos, cannot remain free on bail...

    Latest News

    SEOUL, South Korea — When a group of American lawmakers arrived in South Korea for meetings with government and military officials, President Yoon Suk-yeol...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.